Another phase IIb randomized double-blind placebo-controlled study is ongoing to evaluate the effect of IFN-α-kinoid on the neutralization of the IFN gene signature and its clinical efficacy in SLE patients (NCT02665364). The gene discussed is IFNA2; the disease is systemic lupus erythematosus.